Literature DB >> 12661425

A tale of two colons and two cancers. Distinct carcinogenesis and clinical outcome according to location proximal or distal to the splenic flexure.

P Gervaz1, L Bühler, A Scheiwiller, P Morel.   

Abstract

The central hypothesis explored in this paper is that colorectal cancer (CRC) is a heterogeneous disease. The initial clue to this heterogeneity was provided by genetic findings; however, embryological and physiological data had previously been gathered, showing that proximal (in relation to the splenic flexure) and distal parts of the colon represent distinct entities. Molecular biologists have identified two distinct pathways, microsatellite instability (MSI) and chromosomal instability (CIN), which are involved in CRC progression. In summary, there may be not one, but two colons and two types of colorectal carcinogenesis, with distinct clinical outcome. The implications for the clinicians are two-folds; 1) tumors originating from the proximal colon have a better prognosis due to a high percentage of MSI-positive lesions; and 2) location of the neoplasm in reference to the splenic flexure should be documented before group stratification in future trials of adjuvant chemotherapy in patients with stage II and III colon cancer.

Entities:  

Mesh:

Year:  2003        PMID: 12661425     DOI: 10.1024/1023-9332.9.1.3

Source DB:  PubMed          Journal:  Swiss Surg        ISSN: 1023-9332


  3 in total

1.  Estimation of the familial relative risk of cancer by site from a French population based family study on colorectal cancer (CCREF study).

Authors:  N Andrieu; G Launoy; R Guillois; C Ory-Paoletti; M Gignoux
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

2.  Intrathoracic cancer of the splenic flexure.

Authors:  G Pappas-Gogos; E A Karfis; J Kakadellis; E C Tsimoyiannis
Journal:  Hernia       Date:  2006-12-21       Impact factor: 2.920

3.  KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients.

Authors:  De-Cong Sun; Yan Shi; Yan-Rong Wang; Yao Lv; Huan Yan; Hui Mao; Zhi-Kuan Wang; Zhi-Yong Wu; Wei-Wei Shi; Guang-Hai Dai
Journal:  Sci Rep       Date:  2017-10-30       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.